Cancer screening in theory and in practice.

Improvements in technology have led to a number of tests that can be used to suggest that a patient has a cancer. Advances in cancer biology and medical imaging have led to a number of cancer screening tests. Cancer screening is commonly advocated, but its complexity is often lost in guidelines that have sound-bite quality. It is commonly viewed as of no harm, when in fact there are harms associated with every known screening test. Indeed, many screening experts believe a screening test should only be used when the potential for benefit clearly outweighs the potential for harm. Cancer screening principles are classically within the realm of the epidemiologist. As more screening tests are developed, these principles have become more relevant to the practicing clinician. What is known and what is unknown about screening is distinctly different from what is believed by the public and many practicing clinicians. Many tests have both screening and diagnostic uses, and it is only the context in which these are used that determines whether they are screening or diagnostic. A screening test is done on asymptomatic individuals who receive the test principally because they are of the age or sex at risk for the cancer. A diagnostic test is done on an individual because of clinical suspicion of disease.

[1]  P C Prorok,et al.  A national cancer institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers , 2010, Cancer.

[2]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[3]  M. El-Tamer,et al.  The development of interval breast malignancies in patients with BRCA mutations , 2004, Cancer.

[4]  J. Burdick,et al.  Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. , 2004, JAMA.

[5]  D. Ransohoff.  Virtual colonoscopy--what it can do vs what it will do. , 2004, JAMA.

[6]  Jan Mæhlen,et al.  Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study , 2004, BMJ : British Medical Journal.

[7]  E. Petricoin,et al.  Proteomic approaches in cancer risk and response assessment. , 2004, Trends in molecular medicine.

[8]  P. Pickhardt,et al.  Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. , 2003, The New England journal of medicine.

[9]  Karla Kerlikowske,et al.  Comparison of screening mammography in the United States and the United kingdom. , 2003, JAMA.

[10]  G. Byrnes,et al.  Screening for lung cancer: a systematic review and meta-analysis of controlled trials , 2003, Thorax.

[11]  F. Fazio,et al.  Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results , 2003, The Lancet.

[12]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[13]  E. Stier.  Cervical neoplasia and the HIV-infected patient. , 2003, Hematology/oncology clinics of North America.

[14]  S. Taplin,et al.  Breast cancer screening controversies. , 2003, The Journal of the American Board of Family Practice.

[15]  H. Barry.  Breast self-examination does not reduce mortality. , 2003 .

[16]  Kathleen N Lohr,et al.  Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force , 2002, Annals of Internal Medicine.

[17]  A. Moscicki,et al.  American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer , 2002, CA: a cancer journal for clinicians.

[18]  Michael J Barry,et al.  Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut , 2002, BMJ : British Medical Journal.

[19]  Roberta M Ray,et al.  Randomized trial of breast self-examination in Shanghai: final results. , 2002, Journal of the National Cancer Institute.

[20]  Michael Pignone,et al.  Screening for Colorectal Cancer in Adults at Average Risk: A Summary of the Evidence for the U.S. Preventive Services Task Force , 2002, Annals of Internal Medicine.

[21]  Peter H Gann,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2002, Journal of the National Cancer Institute.

[22]  M. Tuchman,et al.  Screening of infants and mortality due to neuroblastoma. , 2002, The New England journal of medicine.

[23]  Peter C Gøtzsche,et al.  Cochrane review on screening for breast cancer with mammography , 2001, The Lancet.

[24]  R. McLeod.  Screening strategies for colorectal cancer: a systematic review of the evidence. , 2001, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[25]  P. Marcus.  Lung cancer screening: an update. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Ransohoff,et al.  Screening for colorectal cancer [1] (multiple letters) , 2000 .

[27]  J. Brisson,et al.  Tamoxifen and mammographic breast densities. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[28]  P C Prorok,et al.  Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. , 2000, Journal of the National Cancer Institute.

[29]  Lisa M. Schwartz,et al.  Are increasing 5-year survival rates evidence of success against cancer? , 2000, JAMA.

[30]  Peter C Gøtzsche,et al.  Is screening for breast cancer with mammography justifiable? , 2000, The Lancet.

[31]  M. Wallace,et al.  Is Colonoscopy Indicated for Small Adenomas Found by Screening Flexible Sigmoidoscopy? , 1998, Annals of Internal Medicine.

[32]  J. Elmore,et al.  Ten-year risk of false positive screening mammograms and clinical breast examinations. , 1998, The New England journal of medicine.

[33]  J. Hunter,et al.  Cutaneous malignant melanoma in Scotland: incidence, survival, and mortality, 1979-94 , 1997, BMJ.

[34]  D. Ransohoff,et al.  CLINICAL GUIDELINE: PART II: Screening for Colorectal Cancer with the Fecal Occult Blood Test: A Background Paper , 1997, Annals of Internal Medicine.

[35]  A. Berg,et al.  U.S. Preventive Services Task Force: highlights of the 1996 report. , 1997, American family physician.

[36]  Robert C. Bast,et al.  Ovarian cancer: screening, treatment, and followup. , 1995, NIH consensus statement.

[37]  T. Visakorpi,et al.  Aggressiveness of screen-detected breast cancers , 1995, The Lancet.

[38]  T. Bourne,et al.  The Potential Role of Serum CA 125 in an Ultrasound-Based Screening Program for Familial Ovarian Cancer , 1994 .

[39]  P C Prorok,et al.  Prostate Cancer Screening: What We Know and What We Need To Know , 1993, Annals of Internal Medicine.

[40]  S Shapiro,et al.  Report of the International Workshop on Screening for Breast Cancer. , 1993, Journal of the National Cancer Institute.

[41]  B E Storer,et al.  Screening sigmoidoscopy and colorectal cancer mortality. , 1992, Journal of the National Cancer Institute.

[42]  G. Friedman,et al.  A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. , 1992, The New England journal of medicine.

[43]  D. Eddy,et al.  Screening for colorectal cancer , 1992, The Lancet.

[44]  R. Feldman,et al.  Hemoccult screening in detecting colorectal neoplasm: sensitivity, specificity, and predictive value. Long-term follow-up in a large group practice setting. , 1990, Annals of internal medicine.

[45]  V. Zurawski,et al.  Serum CA 125 levels in a group of nonhospitalized women: Relevance for the early detection of ovarian cancer , 1987, Obstetrics and gynecology.